Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

The following is a summary of “Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study,” ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.

Pharming Group excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow. Check out my recommendation for PHAR stock.

Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has received an average recommendation of “Buy” from the seven ...

KalVista Pharmaceuticals, Inc. , today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET.

Theratechnologies Inc.’s THTX share price has dipped by 14.84%, which has investors questioning if this is right time to buy.

Teacher Retirement System of Texas grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 25.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor ...